Back to News
Market Impact: 0.2
Roivant Sets Stage For Phase 2 PHocus Readout Of Mosliciguat In PH-Interstitial Lung Disease
Source: Nasdaq
Healthcare & BiotechProduct Launches
Roivant and subsidiary Pulmovant announced that Phase 2 PHocus study results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented. The provided article text does not disclose efficacy, safety, timing, or financial details, limiting assessment of the clinical readout's significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ROIV0.35
More News
- Moderna shares plunge after leak of partial cancer vaccine data
- 8 Things to Know About the iPhone Duo
- Citizens reiterates Spotify stock rating on product momentum
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna's stock tumbles after reported leak of data for cancer vaccine